Long-term survival of a patient with pulmonary metastatic urothelial carcinoma following metastasectomy.

Abstract

Cisplatin-based systemic chemotherapy is the gold standard for the treatment of patients with metastatic urothelial carcinoma (UC), which is a chemosensitive cancer. However, long-term survival has been deemed disappointing. We describe here a case of UC with solitary pulmonary metastasis who had successfully achieved long-term disease-free survival by combination of cisplatin-based chemotherapy and pulmonary metastasectomy. From the finding of this article, we propose that adjuvant chemotherapy may be considered as a viable option after metastasectomy in low volume pulmonary metastatic UC patients.

• Authors: Kenichi Hasebe, Taku Naiki, Risa Oda, Toshiki Etani, Keitaro Iida, Yosuke Sugiyama, Satoshi Nozaki, Ryosuke Ando, Noriyasu Kawai, Ryoichi Nakanishi, Takahiro Yasui
• Journal: Urology case reports (Urol Case Rep) Vol. 21 Pg. 52-55 (Nov 2018) ISSN: 2214-4420 [Print] United States
• PMID: 30202736 (Publication Type: Case Reports)